Hippocrates Ventures

Investment decisions are led by the firm's founding partners, who evaluate healthcare startups through a combined lens of clinical viability, reimbursement alignment, and founder-market fit. The team operates with a flat structure where core partners share decision-making authority on seed-stage commitments. Specific named decision-makers beyond Aimee Runyon have not been publicly detailed.

The firm relies on operator networks within academic medical centers, digital health accelerators, and clinician-founder communities. This sourcing model prioritizes referrals from practicing physicians and health system executives who encounter workflow pain points firsthand. The New York base provides proximity to major hospital networks and health-tech talent concentrations.

Hippocrates Ventures concentrates on pre-seed and seed-stage healthcare companies, typically participating as a lead or co-lead in first institutional rounds. The firm focuses on pre-revenue and early-traction startups developing digital health platforms, clinical workflow tools, and care delivery models. Multi-stage or growth-equity positions are not part of the stated strategy.

The firm does not invest in biotech therapeutics, medical devices requiring FDA PMA approval, or traditional healthcare services roll-ups. Its mandate is confined to capital-efficient digital health platforms and tech-enabled care delivery models. Biopharma and deep-tech hardware fall outside the investment scope.

Hippocrates Ventures regularly co-invests alongside other early-stage healthcare funds and angel syndicates, particularly in rounds where sector-specialist GPs can provide complementary clinical diligence. The firm does not publicly operate a formal co-investor club, but has participated in syndicated seed rounds alongside health-tech accelerators and other specialist seed funds in New York and Boston. (public record)